Some patients were administered Roxadustat, a hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), which functions by inhibiting the degradation of HIF-1α, thereby increasing its levels and ameliorating anemia. Here, HIF1A is linked to anemia (phenotype).